Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options
Ver/Abrir
Use este enlace para citar
http://hdl.handle.net/2183/32966
Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution 3.0 International License (CC-BY 3.0)
Colecciones
- Investigación (FCS) [1256]
Metadatos
Mostrar el registro completo del ítemTítulo
Approved and off-label uses of obesity medications, and potential new pharmacologic treatment optionsFecha
2010-01-12Cita bibliográfica
Isidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145.
Resumen
[Abstract] Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.
Palabras clave
Drug treatment
Ghrelin
Leptin
Obesity
Orlistat
Sibutramine
Rimonabant
Ghrelin
Leptin
Obesity
Orlistat
Sibutramine
Rimonabant
Descripción
Review
Versión del editor
Derechos
Creative Commons Attribution 3.0 International License (CC-BY 3.0)
ISSN
1424-8247
